- Home
- IMCR
as 04-18-2025 1:37pm EST
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
| Founded: | 2008 | Country: | United Kingdom |
| Employees: | N/A | City: | OXFORDSHIRE |
| Market Cap: | 1.4B | IPO Year: | 2021 |
| Target Price: | $60.90 | AVG Volume (30 days): | 403.7K |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.15 - $62.74 | Next Earning Date: | 05-07-2025 |
| Revenue: | $310,202,000 | Revenue Growth: | 24.36% |
| Revenue Growth (this year): | 20.52% | Revenue Growth (next year): | 8.57% |
Stock Insider Trading Activity of Immunocore Holdings plc (IMCR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | IMCR | Director | Mar 17 '25 | Buy | $29.65 | 807,338 | $23,993,223.80 | 170,007 |
Latest Immunocore Holdings plc News
IMCR Breaking Stock News: Dive into IMCR Ticker-Specific Updates for Smart Investing
MT Newswires
12 days ago
Mizuho Adjusts Price Target on Immunocore Holdings to $33 From $38, Keeps Neutral Rating
GlobeNewswire
17 days ago
Immunocore to present at upcoming investor conferences
Insider Monkey
25 days ago
Immunocore Holdings plc (IMCR): Among Stocks Receiving the Most Insider Love in March
Zacks
a month ago
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last?
GlobeNewswire
a month ago
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
GlobeNewswire
2 months ago
Immunocore to present at upcoming investor conferences
Simply Wall St.
2 months ago
The Immunocore Holdings plc (NASDAQ:IMCR) Full-Year Results Are Out And Analysts Have Published New Forecasts
Simply Wall St.
2 months ago
Immunocore Holdings Full Year 2024 Earnings: Misses Expectations
Compare IMCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMCR Immunocore Holdings plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.